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Summary IMP3 is a fetal protein not expressed in normal adult tissues. IMP3 is an oncoprotein and a useful
biomarker for a variety of malignancies and is associated with reduced overall survival of a number of
them. IMP3 expression and its prognostic value for patients with intrahepatic cholangiocarcinoma (ICC)
have not been well investigated. The molecular mechanism underlying IMP3 expression in human cancer
cells remains to be elucidated. Here we investigated IMP3 expression in ICC and adjacent nonneoplastic
liver in 72 unifocal primary ICCs from a single institute by immunohistochemistry, immunoblotting, and
real-time polymerase chain reaction. IMP3 was specifically expressed in cancer cells but not in the
surrounding normal tissue, and 59 (82%) of 72 ICCs were IMP3 positive by immunohistochemistry.
Among 35 cases with lymphovascular invasion, 26 (74%) showed IMP3 positivity in lymph node
metastases. IMP3 expression was significantly correlated with tumor size, pathological grade, metastasis,
and clinical stage. Kaplan-Meier analysis demonstrated an inverse correlation between IMP3 expression
and overall survival rate. Multivariate analysis revealed that IMP3 was the only risk factor associated with
survival. To further explore the mechanism of IMP3 expression in cancers, we identified 2 CpG islands at
IMP3 proximal promoter. Interestingly, the IMP3 promoter was almost completely demethylated in ICCs
in contrast to densely methylated promoter in normal liver tissues. IMP3 expression is a useful biomarker
for ICCs and can provide an independent prognostic value for patients with ICC. To our knoweldge, this is
the first direct evidence of epigenetic deregulation of IMP3 in human cancer.
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1. Introduction
IMP3 is a family member of insulin-like growth factor II
messenger RNA (mRNA)–binding proteins, which consist
of IMP1, IMP2, and IMP3 [1]. Similar to other family
members, IMP3 plays an important role in RNA trafficking,
stabilization, and localization during early embryogenesis
[2]. IMP3 is expressed in many developing human tissues
such as the epithelium, placenta, and muscle; however, it is
not expressed in normal adult tissue [1,2]. Recent studies
have shown that IMP3 is expressed in some malignant
tumors including adenocarcinomas of the pancreas, kidney,
lung, breast, esophagus, cervix, and endometrium [3-10].
Moreover, IMP3 has been implicated in promoting cell
proliferation, adhesion, and invadopodia formation during
cancer progression [11]. IMP3 has been recognized as an
indicator for cancer progression and metastasis and a
predictor of poor prognosis for many types of cancers
[5,6,8-10].
Intrahepatic cholangiocarcinoma (ICC) is the second most
common primary liver cancer after hepatocellular carcinoma,
accounting for 5% to 15% of all primary liver malignancies
[12]. The global incidence and mortality rate of ICC are
increasing, in contrast to the decreasing trend of extrahepatic
biliary tract cancers [13]. Surgical resection is currently the
most effective treatment and the only therapy associated with
prolonged disease-free survival. After surgical resection, the
5-year overall survival rate ranges from 14% to 40% for
patients with ICC. The poor survival rate is mainly due to the
advanced tumor stage with intrahepatic metastasis at
presentation and early postoperative recurrence [14,15].
Identifying a new biomarker for early detection and to
predict the outcome and to identify new therapeutic target is
needed to improve the management for these patients. Jeng
and coworkers [16] have reported that IMP3 was expressed
in hepatocellular carcinoma, and Riener et al [17] have
shown that IMP3 was expressed in high-grade dysplastic
extrahepatic bile duct epithelium and can be a useful marker
in biliary brushing specimens. However, the expression of
IMP3 and its correlation with clinicopathological features
remain to be elucidated in ICCs.
In this study, we investigated the expression of IMP3 in
ICC, adjacent nonneoplastic liver, and normal-appearing
liver away from ICC by immunohistochemistry (IHC) in 72
surgically resected primary ICCs from a single institute. We
also investigated the correlation of IMP3 expression with
tumor histologic grade, progression, metastasis, clinical
stage, and postoperative survival rate. A recent study by
Ueki et al [18] showed that treatment of an osteosarcoma cell
line with a DNA methyltransferase inhibitor can increase
IMP3 expression, suggesting that epigenetic mechanisms
including DNA demethylation are involved in IMP3
activation in cancer cells. Using EMBOSS CpGPlot, we
identified 2 CpG islands at its proximal promoter. To further
investigate the epigenetic mechanisms by which the
oncofetal protein IMP3 was aberrently expressed in cancer
cells, we analyzed DNA methylation of the IMP3 promoter
in ICCs and normal tissues.
2. Materials and methods
2.1. Case selection
A total of 72 surgically resected unifocal primary ICCs
were collected from 2008 to 2011 at our institute, including
52 archived tissue blocks and 20 freshly frozen tumors. The
study was approved and conducted according to the
regulations of the ethics committee. The specimens were
anonymized and analyzed in a blinded fashion. The patients
included 40 men and 32 women with a mean age of 58.3
years (range, 28-75 years). All patients presented without
jaundice. Serum hepatitis B surface antigen was detected in
23 patients, and anti–hepatitis C virus antibody was positive
in 1 patient. Nineteen patients (26.4%) had hepatic cirrhosis.
Fifty-nine were classified as Child-Pugh class A, and 13 were
class B. None had received transhepatic arterial embolization
or chemotherapy before the surgery. Follow-up time for
survivors ranged from 3 to 46 months (median, 14.9 months).
Fifty-four of the 72 patients were followed up for 1 year
after surgery.
2.2. Histology and tumor staging
All specimens were formalin fixed and paraffin embed-
ded. Histologic sections at 5-μm thickness were stained with
hematoxylin-eosin and reviewed by experienced surgical
pathologists to determine tumor grade and stage. The tumor
was graded based on the criteria proposed by Edmondson
and Steiner [19]. Tumors were staged according to the
seventh edition of American Joint Committee on Cancer
system [20], including 10 stage I (13.9%), 14 stage II
(19.4%), and 48 stage III (66.7%) cases. All surgical margins
were negative, and only completely resected specimens were
included in this study.
2.3. Immunohistochemistry
Formalin-fixed and paraffin-embedded tissue slides
(5 μm) were deparaffinized and rehydrated. Antigen retrieval
was peformed by incubating the tissue slides in 0.01 M citric
acid buffer at 100°C for 10 minutes. After blocking with 3%
H2O2 and 5% fetal bovine serum, the slides were incubated
with a monoclonal antibody against IMP3 (1:100, ab109521;
Abcam, Burlingame, CA) at 4°C overnight. The slides were
then reacted with polymer–horseradish peroxidase reagent.
The peroxidase activity was visualized with diaminobenzi-
dine tetrahydroxychloride solution. The sections were
counterstained with hematoxylin. Dark brown cytoplasmic
staining of at least 1% tumor cells was defined as positive,
and no staining or less than 1% cells stained was defined as
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negative. As a negative control, we replaced the primary
antibody with 5% fetal bovine serum. IMP3 positivity was
graded based on the percentage of tumor cells with positive
staining but not based on stain intensity, including strong
(score 3+; ≥50%), moderate (2+; 10%-49%), and weak
(1+; 1%-9%).
2.4. Immunoblotting
Twenty freshly frozen tissues were isolated for total
protein extraction. An aliquot of protein extract (60 μg) was
separated by 10% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis and electrotransferred to a polyvinylidene
difluoride membrane (Immobilon-P membrane; Millipore,
Bedford, MA).The membrane-bound proteins were incubat-
ed with a primary antibody against IMP3 (1:1000; Abcam) or
β-actin (1:500; Santa Cruz Biotechnology, Santa Cruz, CA).
The membrane was washed 3 times and then incubated with
a secondary antibody for 2 hours at 4°C. Finally, the
immunoreactive signals were detected using an enhanced
chemiluminescence kit (Amersham Pharmacia Biotech,
Piscataway, NJ).
2.5. Real-time polymerase chain reaction
Twenty fresh tumor samples were used to analyze the
mRNA level of IMP3 by real-time polymerase chain reaction
(PCR) performed with the ABI StepOnePlus PCR system
(Applied Biosystems, Foster City, CA). Total RNA was
extracted using TRIZOL reagent, and all primers were
purchased from Invitrogen (Invitrogen, Carlsbad, CA). IMP3
mRNA was normalized with β-actin mRNA level, and results
were presented as the ratio of IMP3 to β-actin. The primers
were as follows: IMP3 forward primer, 5′-ACGAAA-
TATCCCGCCTCATTTAC-3′; IMP3 reverse primer, 5′-
GCAGTTTCCGAGTCAGTGTTCA-3′; β-actin forward
primer, 5′-ACTGGAACGGTGAAGGTGAC-3′, β-actin re-
verse primer, 5′-AGAGAAGTGGGGTGGCTTTT-3′.
2.6. Promoter methylation analysis
The sequence from 2000 base pairs upstream to the
transcription start site (+1) of transcript ENST00000258729
were extracted from Ensembl for analysis (gene ID,
ENSG00000136231). CpG islands at IMP3 proximal
promoter were predicted by EMBOSS CpGPlot. Two CpG
islands were identified, designated as P1 (proximal) and P2
(distal) containing 29 and 19 CpG dinucleotides, respective-
ly. Genomic DNAs (500 ng) extracted from 10 fresh tumors
or 10 nonneoplastic normal-appearing liver tissues were
treated with sodium bisulfite using the MethylCode Bisulfite
Conversion Kit (Invitrogen) following the manufacturer's
instruction. Bisulfite-converted DNAs (30 ng) were used
as templates for PCR amplification of P1 and P2 CpG
islands. The PCR primers were as follows: P1 forward
primer: 5′-AGGTTTTYGAYGATTTTAGTTTT-3′ and
reverse primer: 5′-AAAACCRCAAACACRTTTCTA-3′,
P2 forward primer: 5′-TAGYGTTGAGGAATTGTTTGT-
TAG-3′ and reverse primer: 5′-AACRCAAAAAA-
CRAAAAAAATC-3′. All PCR products were purified
from 1.5% agarose gels using Gel Extraction Kit (Axygen,
Union City, CA) and cloned into the pMD18-T vector
(Promega, Madison, WI).
2.7. Statistics
The data analyses were peformed using SPSS 16.0 (SPSS,
Chicago, IL) and GraphPad Prism v5.0 software (GraphPad,
La Jolla, CA). Correlation between IMP3 expression and
clinicopathological parameters was evaluated by χ2 test and
Fisher exact test. Survival rates were calculated using the
unadjusted Kaplan-Meier method, and difference in survival
curves was analyzed by the log-rank test. Multivariate
analysis was used to evaluate the risk factors associated with
postoperative survival. Two-tailed P values of .05 were
considered statistically significant.
3. Results
3.1. IMP3 expression in ICCs and lymph
node metastasis
We first evaluated the IMP3 expression by IHC in 72
cases of ICC. Fifty-nine (82%) of 72 cases were IMP3
positive, whereas 13 (18%) were negative for IMP3.
Representative IMP3-positive and IMP3-negative tumors
are shown in Fig. 1A and B. IMP3 was predominantly
expressed in tumor nests but not in the surrounding tissue
(Fig. 1C). For 35 cases (48%) with lymphovascular invasion,
26 (74%) of them had IMP3 expression in the lymph node
metastases (Fig. 1D). To further confirm the expression of
IMP3 in ICCs, we selected 20 cases to evaluate the IMP3
expression by 2 additional methods including real-time PCR
and immunoblot using isolated fresh tumors, adjacent
nonneoplastic liver, and normal-appearing liver away from
ICC. As shown in Fig. 2A and B, both IMP3 mRNA and
protein were exclusively detected in tumors but not or at very
low level in nonneoplastic liver or normal-appearing liver
away from ICC in all 20 cases. However, there was no
significant correlation between IMP3 protein expression
level and mRNA level detected by reverse transcriptase
(RT) PCR.
3.2. IMP3expression and clinicopathological features
IMP3 expression in ICC varies considerably in percentage
of tumor cells stained or the intensity. Therefore, IMP3
positivity was categorized into 3 arbitrary levels based on
the percentage of IMP3-positive tumor cells among the
total tumor cell population, as described in Materials and
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Methods: weak, moderate, and strong staining, correspond-
ing to a semiquantitative score of 1+, 2+, and 3+,
respectively. As demonstrated in Fig. 3, among the 59
IMP3-positive cases, IMP3 was assessed as strong,
moderate, and weak in 22 (37%), 15 (25%), and 22 (37%)
cases, respectively.
Next, the correlation between IMP3 expression and a
variety of clinicopathological features was analyzed. As
shown in Table 1, IMP3 expression was more frequently
associated with metastasis (odds ratio [OR], 10.72; P =
.001), higher stage (stages III-IV; OR, 10.71; P = .001),
higher pathological grade (OR, 15.23; P = .002), and larger
tumor size (N5 cm; OR, 2.33; P = .034). Expression of IMP3
was not associated with the patient's age (P = .44) and sex
(P = .171).
3.3. IMP3 expression and clinical outcome
In 54 patients with at least 12 months of follow-up,
Kaplan-Meier analysis showed that patients with IMP3
positivity had a shorter overall postoperative survival time
than did IMP3-negative cases (Fig. 4; P = .010).
Fig. 1 IMP3 was exclusively expressed in primary and metastatic ICCs by IHC. Representative ICCs showing IMP3-negative tumor (A) and
IMP3-positive tumor (B). IMP3-positive tumor surrounded by negatively stained normal tissue (C) and IMP3-positive staining in
representative lymph node metastasis (D). Original magnifications ×100.
Fig. 2 IMP3 mRNA and protein expression in fresh ICC tissues. IMP3 mRNA levels detected in tumor (T), adjacent nonneoplastic liver (P),
and surrounding normal liver away from ICC (N) by real-time PCR (A) and protein levels detected by immunoblot with β-actin serving as a
loading control (B).
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Multivariate analysis revealed that IMP3 was the only
independent risk factor associated with survival with a z
value of 3.03 (Table 2; P = .001). Although tumor stage
was the second most important risk factor, this association
failed to reach statistical significance (Table 2; P = .066).
We observed that all deaths were associated with disease
recurrence, and there was no significant difference in the
survival rate between the cirrhotic and noncirrhotic groups
in this study. Interestingly, IMP3 expression level was
inversely correlated with the 12-month survival rate and
decreased from 90% in IMP3-negative patients to 70%,
Fig. 3 Variable IMP3 expression levels in IMP3-positive ICCs. A, Normal-appearing liver tissue with negative IMP3 staining. As described
above in Materials and Methods, IMP3 expression was semiquantitatively categorized into 3 groups as weak (1+; B), moderate (2+; C), and
strong (3+; D), respectively. Original magnifications ×100.
Table 1 Univariate analysis of IMP3 protein expression and
clinicopathological risk factors for ICC
IMP3 protein expression
Total Positive,
n (%)
OR (95% CI) P
Age (y)
N55 43 34 (79.06) 1 .44
≤55 29 25 (86.20) 1.65 (0.46-5.98)
Sex
Female 32 24 (75.00) 1 .171
Male 40 35 (87.50) 2.33 (0.68-8.0)
Sizes (cm)
≤5 42 31 (73.81) 1 .034 ⁎
N5 30 28 (93.33) 4.97 (1.01-24.38)
Pathological grade
Low 38 26 (68.42) 1 .002 ⁎
High 34 33 (97.05) 15.23 (1.85-124.84)
Tumor stage
I-II 24 14 (58.33) 1 .001 ⁎
III-IV 48 45 (93.75) 10.71 (2.58-44.45)
Metastasis
No 31 20 (64.51) 1 .001 ⁎
Yes 41 39 (95.12) 10.72 (2.16-53.13)
⁎ Statistically significant.
Fig. 4 IMP3 expression correlates with the prognosis of patients
with ICC. The postoperative survival time and the IMP3 expression
level of ICCs were evaluated by Kaplan-Meier in 54 patients with at
least 12 months of follow-up. Patients with IMP3-positive ICC had
a significantly lower survival rate than did those with IMP3-
negative ICC.
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58%, and 32% in 1+, 2+, and 3+ IMP3 positivity cases,
respectively (Table 3; P = .009).
3.4. DNA methylation status at the IMP3 promoter
in ICC
Although IMP3 has been implicated in tumorigenesis and
metastasis, the mechanisms of its deregulation during these
processes have not been well studied. The temporal
suppresion of IMP3 expression after embryogenesis and
the presence of CpG islands at the proximal promoter
prompted us to hypothesize that DNA demethylation
contributes to IMP3 gene activation in cancer cells. In fact,
the RT-PCR results in Fig. 2A showed that IMP3 is
transcriptionally activated in IMP3-positive cancer cells,
although there was no significant correlation between the
mRNA level and IMP3 expression observed. The next
question raised was whether IMP3 expression is associated
with its promoter demethylation. Ideally, to compare IMP3
promoter DNA methylation status in normal bile duct
epithelium and ICC would address this question. Consider-
ing the technical challenge in harvesting the normal bile duct
epithelium, we searched for benign bile duct lesions such as
bile duct hamartoma as a control. However, no cases were
available at this time. Because IMP3 is a fetal protein and not
expressed in normal adult tissues, we decided to obtain an
adjacent normal liver as a surrogate control that does not
express IMP3 by IHC, immunoblot, or RT-PCR (Fig. 2).
Using bisulfite conversion analysis, we found that both P1
and P2 were demethylated in 10 of 10 ICCs, as shown in
Fig. 5A and C, respectively, in contrast to densely
methylated P1 (10/10) and P2 (9/10) in the normal-appearing
liver (Fig. 5B and D, respectively; P = .0001). One case of
P2 region from the normal liver showed a demethylation
pattern that is most likely due to a contamination.
Interestingly, both P1 and P2 (data not shown) were also
demethylated in IMP3-negative tumors by IHC. These data
indicate that an epigenetic mechanism including DNA
methylation at the IMP3 gene promoter contributes to its
temporal gene silencing in normal tissues and that DNA
demethylation is necessary but insufficient in inducing IMP3
expression during cancer initiation or progression.
4. Discussion
ICC is a highly malignant adenocarcinoma of the liver.
Surgical resection is currently the only treatment that
provides a potentially curative outcome. However, the 5-
year survival rate for patients with resectable ICCs is low.
For these reasons, identifying a reliable prognostic marker
will be essential to improve the clinical management for
these patients.
In this study, we demonstrate by 3 different methods that
IMP3 is only expressed in cancer cells, with a sensitivity of
82% and specificity of 100%, consistent with the notion that
IMP3 is a useful marker for malignancies. Furthermore,
IMP3 expression is strongly correlated with tumor grade,
tumor progress, and metastasis, as well as tumor clinical
stage. In Kaplan-Meier analysis, we observed a significant
inverse correlation between IMP3 expression level and 1-
year survival rate. Multivariate analysis revealed that IMP3
is an independent risk factor associated with worse survival.
These data suggest that IMP3 is not only an indicator for
malignancy and metastasis but also a reliable poor prognosis
marker, as previously reported for other types of cancers
[3,7,9,10,16,21-27]. For example, IMP3 positivity is higher
in more aggressive endometrial serous carcinoma than less
aggressive types of endometrial adenocarcinomas [28]. In
contrast, IMP3 would not be a good biomarker or prognostic
factor for prostate adenocarcinoma because its expression is
only slightly correlated with Gleason score and not with
metastasis. [29]. Our data on ICCs strengthen the hypothesis
that high IMP3 expression is prognostic for tumor
aggressiveness and poor clinical outcome.
The mechanistic role of IMP3 in tumorigenesis or tumor
progression remains to be investigated. A few studies have
shown that IMP3 plays a key role in promoting invadopodia
formation, cell proliferation and invasion, anchorage-inde-
pendent growth, and chemoresistance in vitro [11,30-32].
Small interfering RNA knockdown of IMP3 caused reduced
migration and invasion in a cervical cancer cell line [8]. To
our knowledge, there are no published functional data
Table 2 Multivariate analysis of risk factors associated with
survival
Estimate SE z P N z HR
Sex 0.10 0.33 0.31 .753 1.11
Age 0.00 0.02 0.01 .995 1.00
Grade −0.02 0.35 −0.06 .952 0.98
Stage 0.79 0.43 1.84 .066 2.21
Metastasis −0.76 0.77 −0.99 .322 0.47
IMP3 0.63 0.21 3.03 .001 ⁎ 1.87
Size 0.00 0.06 0.02 .987 1.00
⁎ Statistically significant.
Table 3 The 1-year survival rate among differential
expressions of IMP3 protein
IMP3 protein Survival
(mo)
n 1-y
survival
rate (%)
P
≥12 b12
Negative 9 1 10 90.00 .009 ⁎
Weak (score 1+) 7 3 10 70.00
Moderate (score 2+) 7 5 12 58.33
Strong (score 3+) 7 15 22 31.81
⁎ Statistically significant.
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correlating the role of the CpG islands with IMP3 regulation
in cancers. Our methylation studies suggest that epigenetic
deregulation is involved in ICCs, although our study is
limited by using a normal liver as a surrogate control
mentioned above. However, promoter demethylation in
IMP3-negative ICCs suggest that DNA demethylation is
necessary but not sufficient for IMP3 expression in ICC.
Additional factors including histone modifications may be
also involved in this complex process. It would be interesting
to expand IMP3 methylation analysis to other types of
cancers to assess whether expression correlates with
demethylation. Targeting epigenetic modifications including
DNAmethylation and histone modifications is emerging as a
dynamic and efficacious mechanism for cancer therapy [33].
Interestingly, a phase II clinical trial of cancer vaccination
targeting IMP3 for advanced esophageal cancer has been
recently reported [34]. Hypermethylation of CpG island is
generally linked to transcriptional silencing, whereas
demethylation or hypomethylation is associated with
transcriptional activation. Genome-wide hypomethylation
is a well-known phenomenon in cancer biology [35].
However, it remains debatable whether hypomethylation is a
cause or consequence of tumorigenesis. There are limited data
regarding the epigenetic deregulation for IMP3 expression in
carcinogenesis and cancer progression.Whether IMP3 is a key
driver of carcinogenesis or it is merely a manifestation of
genome-wide hypomethylation phenomenon remains to be
investigated. Our data suggested that IMP3 is precisely
silenced through epigenetic modifications including DNA
methylation in normal adult tissues. DNA demethylation and
aberrant IMP3 expression resulting in the aggressiveness of
tumors, although the timing of DNA demethylation and
coplayers during carcinogenesis or progression remain
unclear. Our hypothesis is supported by a recent study
showing that a global DNA methyltransferase inhibitor
5AZaD increased IMP3 expression in an osterosarcoma cell
line [18].
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